Arya Roy
@royaryam
Ass Prof Breast Med Onc Ohio State University! Fellow Roswell Park Comprehensive Cancer Center, IM UAMS, Clinical trials, Immunology, Cancer Health disparities
Thank you very much @ajumathew_ for your kind words! Winning Dr. Gerald Logue #award is truly humbling. Grateful for the invaluable lessons learned under your tutelage. #MentorshipMatters @RoswellPark @RoswellHemOnc @HemOncFellows
My friend, @royaryam , winning a prestigious university level award in the US. She's an alumnus of the Trivandrum Medical College in Kerala. She's a 'triple threat' - a compassionate physician, an astute researcher and a dedicated teacher. I'm so proud of her.
🚨 Do men and women have different outcomes after CAR T-cell therapy? Sex doesn’t seem to impact major hospital outcomes, but there are differences in complications: ✅ Women had higher odds of leukopenia ✅ Lower odds of AKI Mortality & readmission? No significant difference.
👏Congratulations to @quirogad on becoming a Fellow of the American Society of Clinical Oncology (FASCO)!
Incredible talk on Lobular breast cancer by Stuart Schnitt #HarvardBreastCourse @DFCI_BreastOnc
The one & only @hoperugo provides her personal roadmap for the use of PI3K/Akt/mTOR targeting agents #IBC #IBCE25 #GotoPER #MJHLifeSciences
Starting the day with #ASCO25 Review at @OhioStateMedOnc with an stellar lineup of speakers with our chairs @AsrarAlahmadi & @AshishManne a great opportunity for an update and networking with our colleagues from Ohio! @LoganRoofMD @lingbin_meng @HasanovLab @OSUCCC_James
🚴♀️On 8/2, I’ll be cycling 50 miles with @Pelotonia to raise funds for cancer research. 💯% of donations go directly to research #EndingCancer #OneGoal Please consider supporting my ride pelotonia.org/profile/NL9672…
🙋♀️Hello!! How's your schedule this fall? 🌟#WomenInOncology, save Sep 27-28 for #LEAD25! It's a fantastic opportunity for career development, networking with many inspiring and impactful women in oncology! 👉 bioascend.com/lead/ @JulieBrahmer @AnaVManana @KatieLaiMD_MPH…
📢 Recently published study: Obesity & CAR-T outcomes in DLBCL 🧬🩸 Among patients with DLBCL receiving CAR-T therapy, those with obesity had: ⚠️ Higher early mortality (10.6% vs. 4.4%) 🏥 More non-home discharges (18.8% vs. 8.1%) doi.org/10.1159/000545… @OncoKarger
Oncology fellows if you haven’t yet, please take 3 minutes to fill out this survey on your experience with sexual health counseling in cancer patients. Your input means a lot! ✨ @malaksalharbi1 @HemOncFellows @royaryam forms.gle/XHGLfdTJFeVT7e…
🚨 Knowledge, Attitude, and Barriers to Sexual health Counseling for Patients with Breast Cancer - A global study of oncology fellows. Help us improve care by sharing your experience 🩺 forms.gle/XHGLfdTJFeVT7e… @hemeoncfellow
Trastuzumab Deruxtecan Side Effects ILD 2025 Patient Education Ambassadors Program youtu.be/-KN_4SvbHVA?si… via @YouTube In this series, Dr. @royaryam explains what Interstitial Lung Disease (ILD) is, the symptoms of it, and treatment options. For more, please visit…
📝New publication from @royaryam, @OSUCCC_James breast medical oncologist
🚨Proud to share our publication in @JCOOP_ASCO 🧵International Medical Graduates (IMGs) are underrepresented in invited faculty roles at #ASCO Annual Meetings, despite their contributions to original research! @DrChoueiri @NazliDizman @ZiadBakouny @IMG_Oncologists @GlopesMd
What Are Antibody Drug Conjugates 2025 Patient Education Ambassadors Program youtu.be/SKNIN9vwB5Y?si… via @YouTube GRACE's 2024-2025 Patient Education Ambassadors discuss topics in cancer, including leukemia, antibody drug conjugates, and more. In this series, Dr. @royaryam…
Side Effects of Antibody Drug Conjugates 2025 Patient Education Ambassadors Program youtu.be/Ve340QUHKO0?si… via @YouTube In this series, Dr. @royaryam discusses the potential side effects for patients being treated with antibody drug conjugates. For more, please visit…
Submit your abstracts for the 5th Binaytara Precision Oncology Summit. All abstracts, including case reports, are welcome across topics relevant to precision oncology. Submit NOW: abstracts.binaytara.org/conference/5th…
After saying goodbye to anthracyclines— are we ready to also drop the carbo for our patients with stage II HER2+ breast cancer? Check out this discussion with friends and superstar breast oncs @YAbdouMD @JAMouabbi — powered by @OncLive
Sign up for free to read our exclusive June web feature! 🔐 This feature explores the evolution of the HER2-positive #BreastCancer landscape, including data from the phase 3 neoCARHP study and the phase 2 CompassHER2 pCR trial. @YAbdouMD @PTarantinoMD @JAMouabbi
Evaluation and Treatment of Iron Deficiency for the Practicing Oncologist | JCO Oncology Practice ascopubs.org/doi/10.1200/OP… @JCOOP_ASCO @ASCO @JCO_ASCO @OncoAlert
📢 IMP work from @OffCMCVellore & Adyar @CI_WIA, published in @BMJ_SPCare. 📈 Timely early palliative care referrals rose from 30–37% ➡️ 60–66% via sustainable QI interventions. 📝 Read doi.org/10.1136/spcare… 👏 Congrats @drmpk91, Jewell, @JeniferJeba Ma’am & the team!
Organizing the inaugural cancerconclave.com in Kerala. We have lined up an interesting array of topics on cancer care and control. #AMPOK Join us on livestream. Link to follow.
Starting tomorrow
Organizing the inaugural cancerconclave.com in Kerala. We have lined up an interesting array of topics on cancer care and control. #AMPOK Join us on livestream. Link to follow.